JP2023533937A5 - - Google Patents
Info
- Publication number
- JP2023533937A5 JP2023533937A5 JP2023500008A JP2023500008A JP2023533937A5 JP 2023533937 A5 JP2023533937 A5 JP 2023533937A5 JP 2023500008 A JP2023500008 A JP 2023500008A JP 2023500008 A JP2023500008 A JP 2023500008A JP 2023533937 A5 JP2023533937 A5 JP 2023533937A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- subject
- composition according
- antibody
- months
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2026010946A JP2026082887A (ja) | 2020-06-29 | 2026-01-27 | 抗組織因子抗体-薬物コンジュゲートおよびがん治療におけるその使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063045448P | 2020-06-29 | 2020-06-29 | |
| US63/045,448 | 2020-06-29 | ||
| US202063094571P | 2020-10-21 | 2020-10-21 | |
| US63/094,571 | 2020-10-21 | ||
| PCT/EP2021/067855 WO2022002940A1 (en) | 2020-06-29 | 2021-06-29 | Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026010946A Division JP2026082887A (ja) | 2020-06-29 | 2026-01-27 | 抗組織因子抗体-薬物コンジュゲートおよびがん治療におけるその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023533937A JP2023533937A (ja) | 2023-08-07 |
| JP2023533937A5 true JP2023533937A5 (cg-RX-API-DMAC7.html) | 2024-06-19 |
Family
ID=76744843
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023500008A Pending JP2023533937A (ja) | 2020-06-29 | 2021-06-29 | 抗組織因子抗体-薬物コンジュゲートおよびがん治療におけるその使用 |
| JP2026010946A Pending JP2026082887A (ja) | 2020-06-29 | 2026-01-27 | 抗組織因子抗体-薬物コンジュゲートおよびがん治療におけるその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026010946A Pending JP2026082887A (ja) | 2020-06-29 | 2026-01-27 | 抗組織因子抗体-薬物コンジュゲートおよびがん治療におけるその使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230263902A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4171652A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2023533937A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230028492A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116322787A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021299947A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022025105A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3183898A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL299334A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022015375A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202216210A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022002940A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240134250A (ko) | 2018-01-04 | 2024-09-06 | 아이코닉 테라퓨틱스, 인코포레이티드 | 항-조직 인자 항체, 항체-약물 결합체, 및 관련 방법 |
| TWI841554B (zh) | 2018-03-21 | 2024-05-11 | 丹麥商珍美寶股份有限公司 | 以鉑為主之劑與抗組織因子抗體-藥物共軛物的組合治療癌症之方法 |
| JP7460608B2 (ja) | 2018-05-07 | 2024-04-02 | ジェンマブ エー/エス | 抗pd-1抗体と抗組織因子抗体-薬物コンジュゲートとの組み合わせを用いるがんの治療方法 |
| TWI844571B (zh) | 2018-10-30 | 2024-06-11 | 丹麥商珍美寶股份有限公司 | 使用抗血管內皮生長因子(vegf)抗體與抗組織因子(tf)抗體-藥物共軛體之組合以治療癌症之方法 |
| PE20221004A1 (es) * | 2019-07-03 | 2022-06-15 | Iconic Therapeutics Inc | Conjugados de anticuerpos y farmacos anti-factor tisular y metodos relacionados |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2183662B (en) | 1985-04-01 | 1989-01-25 | Celltech Ltd | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
| US5981216A (en) | 1985-04-01 | 1999-11-09 | Alusuisse Holdings A.G. | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US5750172A (en) | 1987-06-23 | 1998-05-12 | Pharming B.V. | Transgenic non human mammal milk |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
| US5879936A (en) | 1988-04-18 | 1999-03-09 | Aluguisse Holding A.G. | Recombinant DNA methods, vectors and host cells |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
| US5891693A (en) | 1990-01-25 | 1999-04-06 | Alusuisse Holdings A.G. | Recombinant DNA methods vectors and host cells |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| AU2235992A (en) | 1991-06-14 | 1993-01-12 | Genpharm International, Inc. | Transgenic immunodeficient non-human animals |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| EP0593592B1 (en) | 1991-07-08 | 1998-03-25 | The University Of Massachusetts At Amherst | Thermotropic liquid crystal segmented block copolymer |
| GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
| US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
| AU693436B2 (en) | 1993-03-09 | 1998-07-02 | Genzyme Corporation | Isolation of components of interest from milk |
| AU6819494A (en) | 1993-04-26 | 1994-11-21 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US5663149A (en) | 1994-12-13 | 1997-09-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides |
| CN1399645A (zh) | 1999-07-29 | 2003-02-26 | 米德列斯公司 | Her2/neu的人单克隆抗体 |
| NZ517202A (en) | 1999-08-24 | 2004-05-28 | Medarex Inc | Human CTLA-4 antibodies and their uses |
| DE60131456T2 (de) | 2000-11-30 | 2008-07-10 | Medarex, Inc., Milpitas | Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern |
| US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| WO2003026577A2 (en) | 2001-09-24 | 2003-04-03 | Seattle Genetics, Inc. | P-amidobenzylethers in drug delivery agents |
| ES2369542T3 (es) | 2002-07-31 | 2011-12-01 | Seattle Genetics, Inc. | Conjugados de auristatina y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa. |
| ES2605443T3 (es) | 2003-11-06 | 2017-03-14 | Seattle Genetics, Inc. | Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia |
| DK2383295T3 (en) | 2003-12-10 | 2015-06-15 | Squibb & Sons Llc | Ip-10 antibodies and uses thereof |
| CA2556752C (en) | 2004-02-23 | 2016-02-02 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
| US7837980B2 (en) | 2004-03-02 | 2010-11-23 | Seattle Genetics, Inc. | Partially loaded antibodies and methods of their conjugation |
| JP2008519863A (ja) | 2004-11-12 | 2008-06-12 | シアトル ジェネティクス インコーポレイティッド | N末端にアミノ安息香酸単位を有するオーリスタチン |
| EP1898529A1 (en) | 2005-06-28 | 2008-03-12 | Pioneer Corporation | Broadcast receiving apparatus, interference detecting apparatus and interference detecting method |
| HUE035853T2 (en) | 2005-07-18 | 2018-05-28 | Seattle Genetics Inc | Beta-glucuronide-linker-drug conjugates |
| JP5588866B2 (ja) | 2007-08-10 | 2014-09-10 | メダレックス エル.エル.シー. | Hco32およびhco27、ならびに関連実施例 |
| UA109633C2 (uk) | 2008-12-09 | 2015-09-25 | Антитіло людини проти тканинного фактора | |
| JP6055404B2 (ja) | 2010-06-15 | 2016-12-27 | ゲンマブ エー/エス | 組織因子に対するヒト抗体薬物結合体 |
| SI3071237T1 (sl) | 2013-11-21 | 2024-11-29 | Genmab A/S | Liofilizirana formulacija konjugata protitelo-zdravilo |
| BR112020008593A2 (pt) * | 2017-11-02 | 2020-10-20 | Genmab A/S | método de tratamento de câncer cervical em um indivíduo |
-
2021
- 2021-06-29 KR KR1020237002734A patent/KR20230028492A/ko active Pending
- 2021-06-29 CN CN202180053328.8A patent/CN116322787A/zh active Pending
- 2021-06-29 CA CA3183898A patent/CA3183898A1/en active Pending
- 2021-06-29 AU AU2021299947A patent/AU2021299947A1/en active Pending
- 2021-06-29 US US18/010,783 patent/US20230263902A1/en active Pending
- 2021-06-29 WO PCT/EP2021/067855 patent/WO2022002940A1/en not_active Ceased
- 2021-06-29 MX MX2022015375A patent/MX2022015375A/es unknown
- 2021-06-29 JP JP2023500008A patent/JP2023533937A/ja active Pending
- 2021-06-29 TW TW110123815A patent/TW202216210A/zh unknown
- 2021-06-29 BR BR112022025105A patent/BR112022025105A2/pt unknown
- 2021-06-29 IL IL299334A patent/IL299334A/en unknown
- 2021-06-29 EP EP21737082.4A patent/EP4171652A1/en active Pending
-
2026
- 2026-01-27 JP JP2026010946A patent/JP2026082887A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lee et al. | An open-label, randomized, parallel, phase II trial to evaluate the efficacy and safety of a cremophor-free polymeric micelle formulation of paclitaxel as first-line treatment for ovarian cancer: a Korean Gynecologic Oncology Group study (KGOG-3021) | |
| Ricci et al. | Gemcitabine monotherapy in elderly patients with advanced non-small cell lung cancer: a multicenter phase II study | |
| JP2025020147A5 (cg-RX-API-DMAC7.html) | ||
| Kornek et al. | Effective combination chemotherapy with paclitaxel and cisplatin with or without human granulocyte colony-stimulating factor and/or erythropoietin in patients with advanced gastric cancer | |
| Hwang et al. | A multi-center, open-label, randomized phase III trial of first-line chemotherapy with capecitabine monotherapy versus capecitabine plus oxaliplatin in elderly patients with advanced gastric cancer | |
| KR102943054B1 (ko) | 면역 체크포인트 저해약 및 폴피리녹스 요법과의 병용에 의한 암 치료 | |
| JP2012509889A5 (cg-RX-API-DMAC7.html) | ||
| ten Tije et al. | Weekly paclitaxel as first-line chemotherapy for elderly patients with metastatic breast cancer. A multicentre phase II trial | |
| DK2656844T3 (en) | ANTINEOPLASTIC COMBINATIONS CONTAINING HKI-272 AND VINORELBINE | |
| JP2003533485A5 (cg-RX-API-DMAC7.html) | ||
| IL312038A (en) | Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer | |
| JP2021528496A5 (cg-RX-API-DMAC7.html) | ||
| US11419862B2 (en) | Quinoline derivative for treatment of nasopharyngeal carcinoma | |
| TW201127384A (en) | Therapeutic combination comprising a Cdc7 inhibitor and an antineoplastic agent | |
| JP2016515619A5 (cg-RX-API-DMAC7.html) | ||
| CA2902144A1 (en) | Methods and compositions for treating cancers having acquired resistance to prior chemotherapeutic and targeted drugs using carboxyamidotriazole orotate | |
| CN1674908A (zh) | erb B激酶抑制剂和抗肿瘤疗法的联合治疗 | |
| JP2024539476A (ja) | 医薬組成物およびその使用 | |
| JP2025163103A (ja) | 放射線および/または抗がん治療補助療法としてアデノシン二リン酸リボースの活用 | |
| CN115461079A (zh) | 用于治疗肾癌的联用药物 | |
| CN112043831A (zh) | 用于联合治疗乳腺癌的喹啉类化合物 | |
| Iwase et al. | A phase II multi-center study of triple therapy with paclitaxel, S-1 and cisplatin in patients with advanced gastric cancer | |
| JP2005511663A5 (cg-RX-API-DMAC7.html) | ||
| JP2005511663A (ja) | 癌に対する医薬の製造のための、他の抗腫瘍性剤と組み合わせたファルネシルタンパク質トランスフェラーゼインヒビターの使用 | |
| Basha et al. | A review on chemotherapy induced complications in cancer patients |